Compare KOPN & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOPN | MNOV |
|---|---|---|
| Founded | 1984 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.8M | 70.4M |
| IPO Year | 2025 | 2004 |
| Metric | KOPN | MNOV |
|---|---|---|
| Price | $4.50 | $1.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.69 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 3.5M | 51.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.03 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,530,311.00 | ★ $2,360,807.00 |
| Revenue This Year | $50.07 | N/A |
| Revenue Next Year | $33.33 | $180.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 46.53 | ★ 194.15 |
| 52 Week Low | $1.81 | $1.17 |
| 52 Week High | $6.61 | $1.96 |
| Indicator | KOPN | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 48.51 | 70.14 |
| Support Level | $4.20 | $1.28 |
| Resistance Level | $4.52 | $1.80 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 24.75 | 74.26 |
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.